Endurant Capital Management LP
- SEC CIK
- 0001633055
- Latest filing
- May 7, 2024
ADAPY holding history
Adaptimmune Therapeutics PLC in every 13F filed by Endurant Capital Management LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ADAPY overviewAll 13F holders of ADAPYFull Q1 2024 holdings
- Shares (Q4 2023)
- 0
- Sold out in Q4 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2023 | 0 | $0 | 0.0% | −311,944−100.0% | Sold out | Holders |
| Q3 2023 | 311,944 | $243.3K | 0.2% | −509,094−62.0% | Reduced | Holders |
| Q2 2023 | 821,038 | $759.5K | 1.0% | −839,797−50.6% | Reduced | Holders |
| Q1 2023 | 1,660,835 | $1.81M | 0.9% | −72,401−4.2% | Reduced | Holders |
| Q4 2022 | 1,733,236 | $2.53M | 1.0% | −55,281−3.1% | Reduced | Holders |
| Q3 2022 | 1,788,517 | $1.92M | 0.6% | −35,548−1.9% | Reduced | Holders |
| Q2 2022 | 1,824,065 | $3.10M | 1.2% | −336,825−15.6% | Reduced | Holders |
| Q1 2022 | 2,160,890 | $4.45M | 1.3% | +1,263,311+140.7% | Added | Holders |
| Q4 2021 | 897,579 | $3.37M | 0.9% | −19,909−2.2% | Reduced | Holders |
| Q3 2021 | 917,488 | $4.74M | 1.4% | −621,947−40.4% | Reduced | Holders |
| Q2 2021 | 1,539,435 | $6.56M | 1.8% | +623,724+68.1% | Added | Holders |
| Q1 2021 | 915,711 | $4.86M | 1.3% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.